A prospective, randomized, open label, comparative study of efficacy and tolerability of oral itraconazole versus combination therapy with oral itraconazole and oral terbinafine in treatment of dermatophytosis
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262865Keywords:
Antifungal drugs, Dermatophytosis, Itraconazole, TerbinafineAbstract
Background: Superficial dermatophytosis, caused by fungi like Trichophyton and Microsporum, affects skin, hair and nails, presenting as round, red, scaly patches with itching. Generally, topical antifungals are common preferred treatment, while extensive infections and immunocompromised patients often require systemic oral treatments due to frequent relapses and resistance to topical terbinafine. This study compares itraconazole monotherapy with combination therapy of itraconazole and terbinafine to optimize treatment.
Methods: The study was conducted at Kempe Gowda Institute of Medical Sciences Hospital & Research Centre, Bengaluru, the study included 152 clinical and 10% KOH smear confirmed superficial dermatophytosis patients. Participants were randomly assigned to Group A (77 received oral itraconazole 100 mg twice daily for 3 weeks) and Group B (75 received oral itraconazole 100 mg twice daily plus oral terbinafine 250 mg once daily for 3 weeks). Participants were followed -ups at 3, 6 and 9 weeks for symptoms, KOH smear test results, clinical response and rescue medication use.
Results: Group B had a higher proportion of complete recoveries without relapse (p value 0.00775). No significant differences were found between the groups in terms of symptom severity, KOH test results, clinical response or rescue medication use, indicating comparable effectiveness.
Conclusions: Combination therapy with itraconazole and terbinafine was more effective than itraconazole alone in achieving relapse-free recovery in dermatophytosis patients. Both regimens were well-tolerated, suggesting combination therapy as a potentially better approach for fungal infections. This study supports combination therapy as a cost-effective treatment for tinea infections.
Metrics
References
Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, et al. The unprecedented epidemic like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. Indian J Dermatol Veneral Leprol. 2021;87:154-75. DOI: https://doi.org/10.25259/IJDVL_301_20
Nenoff P, Verma SB, Vasani R, Burmester A, Hipler UC, Wittig F, et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes: A molecular study. Mycoses. 2019;62(4):336-56. DOI: https://doi.org/10.1111/myc.12878
Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90(10):702-10.
Salunke P, Someshwar S, Bhobe M. Efficacy of daily oral Terbinafine versus pulse fluconazole therapy in the treatment of tinea corporis, tinea cruris and tinea faciei: A Comparative Study. MGM J Med Sci. 2020;7:10-5. DOI: https://doi.org/10.4103/mgmj.MGMJ_30_20
Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study. Indian J Pharmacol. 2019;51(2):116-119. DOI: https://doi.org/10.4103/ijp.IJP_578_17
Singh S, Chandra U, Anchan VN, Verma P, Tilak R. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. Br J Dermatol. 2020;183(5):840-846. DOI: https://doi.org/10.1111/bjd.19146
Begum S. Comparison of efficacy and safety of oral use of terbinafine and itraconazole for the treatment of Tinea paedis: A randomized controlled parallel group open labeled trial with clinico-mycological correlation. Comm Based Med J. 2023;12(2):150–6 DOI: https://doi.org/10.3329/cbmj.v12i2.68346
Kabir MH, Khan MAL, Khan MSI, Karim ATMR, Rahman MM, Jamil AM. Study on efficacy and safety of terbinafine vs. Itraconazole in the treatment of Tinea Pedis. TAJ J Teach Assoc. 2023;36(1):75–82. DOI: https://doi.org/10.3329/taj.v36i1.68302
George M, Chaudhary RG, Rana D. Comparative evaluation of efficacy of terbinafine and itraconazole in treatment of tinea cruris. Int J Basic & Clin Pharmacol. 2019;8(7):1460–6. DOI: https://doi.org/10.18203/2319-2003.ijbcp20192642
Shumi FR, Shamim SMA, Afroz R, Sharmin S, Kabir S, Mumtaz F. Combination of systemic terbinafine (250 mg) twice daily and itraconazole (100 mg) twice in a pulse dose in resistant tinea infection. Int J Res Dermatol. 2022;8:199-205. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20220150
Koregol S, Naik SR, Hosthota A, Koregol AC. A comparative study of efficacy of oral itraconazole, terbinafine and fluconazole: a clinical trial. International J Res Dermatol. 2021;7:435. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20211705
Singh S. Effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole, terbinafine) in current epidemic of altered dermatophytosis in India: A randomized pragmatic trial. medRxiv. 2019:19:3541. DOI: https://doi.org/10.1101/19003541
Shah B, Shah S, Jangid N, Dhoot D, Deshmukh G, Barkate H. Comparative evaluation of efficacy and safety of terbinafine and itraconazole in the management of tinea corporis et cruris. IP Indian J Clin Exp Dermatol. 2020;6(3):231-6. DOI: https://doi.org/10.18231/j.ijced.2020.047
Brigida S, Elizabeth AA, Soujania G, Poornima RP. A comparative study of safety and efficacy of Oral Terbinafine and Itraconazole in patients of Tinea Corporis/ Tinea Cruris infection, A randomized open label parallel group study. Biomed Pharmacol J. 2021;14(3):1543–9. DOI: https://doi.org/10.13005/bpj/2256
Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529-34. DOI: https://doi.org/10.1080/mmy.40.5.529.534
Downloads
Published
How to Cite
Issue
Section
